Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

Read More

Overview

Feature Articles

Latest Prostate Cancer News and Research

New approach harnesses disease-causing proteins to combat cancer

New approach harnesses disease-causing proteins to combat cancer

Renalytix AI and University of Utah announce partnership to improve kidney health

Renalytix AI and University of Utah announce partnership to improve kidney health

High-throughput genetic analysis can help dissect the mechanism of disease inheritance

High-throughput genetic analysis can help dissect the mechanism of disease inheritance

Polygenic hazard score improves prediction of prostate cancer risk in multi-ethnic populations

Polygenic hazard score improves prediction of prostate cancer risk in multi-ethnic populations

Psychosocial factors may contribute to dropout of patients from peritoneal dialysis

Psychosocial factors may contribute to dropout of patients from peritoneal dialysis

Targeting MAPK4 enzyme may be a potential new strategy to combat prostate cancer

Targeting MAPK4 enzyme may be a potential new strategy to combat prostate cancer

Researchers track how Osmium reacts in a single cancer cell

Researchers track how Osmium reacts in a single cancer cell

Researchers identify molecular link between inflammatory signaling molecule and a main oncogene

Researchers identify molecular link between inflammatory signaling molecule and a main oncogene

Mathematical model reveals how cell turnover determines the success of adaptive therapy

Mathematical model reveals how cell turnover determines the success of adaptive therapy

New model predicts which patients will gain most from PSMA PET scan

New model predicts which patients will gain most from PSMA PET scan

New urine test could avoid unnecessary prostate cancer biopsies

New urine test could avoid unnecessary prostate cancer biopsies

Genomic test may help guide treatment decisions for patients with recurrent prostate cancer

Genomic test may help guide treatment decisions for patients with recurrent prostate cancer

Researchers analyze overall survival rate of prostate cancer patients treated with melatonin

Researchers analyze overall survival rate of prostate cancer patients treated with melatonin

Study reveals why Black men with prostate cancer have greater survival benefits from immunotherapy

Study reveals why Black men with prostate cancer have greater survival benefits from immunotherapy

Study shows efficacy of radionuclide therapy–immunotherapy combination in prostate cancer model

Study shows efficacy of radionuclide therapy–immunotherapy combination in prostate cancer model

HKBU and CUHK jointly develop Spermine Risk Score for diagnosis of prostate cancer

HKBU and CUHK jointly develop Spermine Risk Score for diagnosis of prostate cancer

Cancer patients less likely to receive life-saving therapy when suffering a heart attack

Cancer patients less likely to receive life-saving therapy when suffering a heart attack

New process separates beneficial glucocorticoids from unwanted side-effects

New process separates beneficial glucocorticoids from unwanted side-effects

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug

Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug